Home
About
Overview
Sharing Data
ORCID
Help
History (1)
The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer.
The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer. Nat Metab. 2020 12; 2(12):1401-1412.
View in:
PubMed
subject areas
Animals
Antineoplastic Agents
Azaserine
Carcinoma, Non-Small-Cell Lung
Cell Line, Tumor
Enzyme Inhibitors
Gene Expression Regulation, Neoplastic
Glutamine-Fructose-6-Phosphate Transaminase (Isomerizing)
Hexosamines
Humans
Lung Neoplasms
Metabolic Networks and Pathways
Metabolomics
Mice
Mutation
Proto-Oncogene Proteins p21(ras)
Survival Analysis
Tumor Stem Cell Assay
authors with profiles
Brandon Faubert